Citations

Clear

1053 citation(s) found for "Andre, F".

Evolution of the Evidence for the Management of COVID-19 in Hematologic Malignancies: A Systematic Literature Review of Remdesivir
Mozaffari, Essy, Malin, Jakob J , Rawal, Aaditya , Kaiser, Emily , Nicolae, M, Schmidt, Elvira , Oppelt, Thomas F , Chiang, Mel, Sax, Paul E. , Bartoletti, Michele , Doi, Yohei , Loubet, Paul , Rivera, Christina G. , Poulakou, Garyphallia , Carlo‐Stella, Carmelo , Kalil, André C.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7750-7750

10.1182/blood-2024-200253 Get It

Background: Patients with immunocompromising conditions, including those affected by hematologic malignancies, have a disproportionately high burden of morbidity and mortality related to COVID-19 compared to individuals without such conditions.Clinical practice guidelines (CPGs) recommend the use of remdesivir, a broad-spectrum antiviral, for treatment of mild to severeCOVID-19 in immunocompetent patients not requiring invasive mechanical ventilation. While the CPGs issued by the World Health Organization (WHO, 2023), National Institutes of Health (NIH, 2023) and the Infectious Diseases Society of America (IDSA, 2022) also recommended the use of remdesivir in patients with immunocompromising conditions at high risk for severe disease, there was limited evidence available at the time the recommendations were communicated, more than two years after the start of the pandemic. The European Conference on Infections in Leukemia (ECIL, 2022) guidelines include remdesivir among the treatment options for mild to moderate COVID-19 patients with hematologic malignancies. The lack of evidence for treatment efficacy and safety in patients with immunocompromising conditions, a population underrepresented or excluded from clinical trials, was mentioned in CPGs as a knowledge gap and as need for further research. In this research, we summarize the evidence for remdesivir efficacy and safety for treatment of COVID-19 in hospitalized patients with hematologic malignancies accumulated since the start of the pandemic. Methods: We systematically searched MEDLINE, Embase and Cochrane Library databases from January 2019 through December 2023 for interventional and observational studies examining remdesivir efficacy and safety. Case reports and case studies were excluded. A dual-reviewer approach was used for screening and data extraction. Results: Of the 7,654 references retrieved through the implementation of the extensive search strategy 59 (0.8%) reporting on patients with hematologic malignancies, unspecified cancers, or immunodeficiencies were identified and reviewed in full text. Only eight unique studies (8 of 59) were conducted in patients with hematologic malignancies, of which two reported remdesivir use in a minority of participants (n<5) and were excluded from further analyses. The remaining six studies, of which four were peer-reviewed original articles, one was a letter to editor and the last was a conference abstract, used a retrospective cohort design and reported efficacy outcomes for a combined total of 1,579 individuals across the studies. Three of the six studies were conducted during the pre-Omicron variant era (November 2021) while the remaining three started data collection in December 2021. There were four studies reporting number of deaths or the mortality rate, while a fifth study based on medical chart reviews of 313 patients in Israel found a significantly reduced risk of mortality among remdesivir recipients compared to patients not receiving remdesivir (OR: 0.297; 95% CI: 0.105, 0.834). In addition, a study including 466 patients from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Registry reported mortality among remdesivir treated group related to baseline disease progression, use of corticosteroids for COVID-19 therapy and the presence of coinfections while B-cell malignancy as underlying disease, severe COVID-19, late antiviral initiation (≥5 days after first positive PCR) and longer treatment duration (≥5 days) were factors significantly associated with prolonged viral shedding. The same Spanish study reported safety outcomes indicating that adverse events of grade 3 or above were rare, occurring in 0.5% of remdesivir treated patients. Conclusion: Despite the call for research to fill the knowledge gap signaled by the CPGs, our comprehensive systematic literature review identified only a few publications conducted since the start of the pandemic in patients with hematological malignancies. In the current endemic era, these patients are among the most at risk for severe outcomes and COVID-19 related hospitalizations. While the limited evidence suggests that remdesivir use can reduce mortality in patients with hematologic malignancies, additional research will be instrumental to inform development and updating of evidence-based recommendations to support and guide clinical management of oncology patients.
NCOG-29. HIGHER HYPOTHALAMIC RADIATION DOSE AND FEMALE GENDER ARE RELATED TO HIGHER SELF-REPORTED FATIGUE
Neth, Bryan J. , Alden, Eva , Uhm, Joon H. , D’Andre, Stacy D. , Amundson, A., Vora, Sujay A., Mahajan, Anita , Brown, Paul D. , Breen, William G. , Neth, Byran J. , Sener, Uğur , Burns, Terry C. , Routman, David M. , Trifiletti, Daniel M. , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii230-viii231

10.1093/neuonc/noae165.0911 Get It

Abstract BACKGROUND Fatigue is among the most common symptoms managed by patients with cancer. Hypothalamic pituitary axis dysfunction has an established role in a subset of patients with fatigue. Our primary aim was to longitudinally assess the impact of hypothalamic radiation exposure to patient self-reported fatigue. METHODS We included a sample of patients who received radiation therapy treated at a single institution from 2014-2024. The PROMIS-10 questionnaire (“How would you rate your fatigue on average,” scale 1-5) was used in standard clinical practice, with measures from 6 time points over 2 years. We performed descriptive statistics. Linear mixed models were used to assess the impact of hypothalamic radiation dose on fatigue scores. Mixed models were controlled for gender, age, time, tumor category (CNS vs. non-CNS), and modality (photon vs. proton). Models were fit with random intercepts for each Patient ID. RESULTS 1092 patients (43% female) with a median age of 54 years (range: 18-92) were included. Most patients were treated for CNS cancer (76%), with about 50% each photon and proton. Median hypothalamus radiation dose was 1306 cGy (range: 0.01-6138). Mean baseline fatigue (2.4) increased after treatment (2.7) remaining elevated at 3- and 6-months post-treatment (2.6, 2.5), returning near baseline at 1- and 2-years post-treatment (2.4, 2.3). Higher radiation dose (Estimate (SE): 0.014 (0.006), p=0.0266) and CNS cancer treatment (0.11 (0.051), p=0.0319) were significant predictors of higher fatigue in the mixed model. Male patients (-0.16 (0.042), p=0.0001) and time (-0.003 (0.0016), p=0.0398) were associated with lower fatigue. Age and treatment modality were not significant predictors of fatigue. CONCLUSIONS We found that higher hypothalamic radiation dose was related to more self-reported fatigue, which peaked by 6 months. This effect was seen more prominently in female patients and those treated for CNS disease. Treatment modality and age did not influence fatigue scores.
Barriers to global engagement for African researchers: A position paper from the Alliance for Medical Research in Africa (AMedRA)
Gaye, Bamba , Singh, Gurbinder , Gaye, Ngone Diaba, Ka, Mame Madjiguène , Seck, Daouda, Gueye, Khadidiatou, Kitara, David Lagoro , Lassale, Camille , Anne, Malick, Diaw, Mor , Gaye, Magaye, Fall, Abdou Salam , Diongue, Aïda, Seck, Ibrahima , Belkhadir, Jamal , Wone, I, Gueye, Sérigne Maguèye , Sow, Papa Salif , Kohen, Jamal Eddine, Vogelsang, Dorothea, Mbaye, Maïmouna Ndour, Liyong, Elisabeth Alice, Kengne, André Pascal , Sougou, Ndèye Mariéme, Ba, Awa, Tukakira, John, Lorenz, Thiess , Kabore, Elisé , Muzumala, Malaizyo Gabriel, Olanrewaju, A. I., Jaiteh, Lamin , Délicat-Loembet, Lucrèce M. , Alson, Aimée Olivat Rakoto, Niang, Khadim, Mwebaze, Ernest , Nakatumba‐Nabende, Joyce , Machuve, Dina , Adie, Prestone, Hanne, Fatoumata, Sougou, Marième, Koffi, Kouassi Gustave, Luwanda, Lameck, Mekonnen, Demeke, Ebeid, Fatma Soliman Elsayed , Enama, Jean Paul, Zeba, Mohamadi , Guedou, Fernand Aimé, Mbélesso, Pascal , Carter, Jennifer , Coulibaly, Bakary, Dramé, Mohamed Lamine, Mouanga, Alain Maxime , Lacroix, Philippe, Diagana, Mouhamadou , Ekouévi, Didier Koumavi , Houinato, Dismand, Faye, Adama , Wambugu, Vivien , Kamaté, Jean, Lalika, Mathias , Ale, Boni Maxime , Fall, Ibrahima Socé , Samb, Abdoulaye, Jobe, Modou , Isiozor, Nzechukwu Michael , Gaye, Ngone Diaba, Seck, Daouda , Seck, Sidy Mohamed , Sow, Abdourahmane , Diongue, Aïda, Lamptey, Roberta , Sobngwi, Eugène , Muzumala, Malaizyo G. , Maina, Ciira wa , Adie, Prestone, Tine, Roger Clément Kouly , Koffi, K. G. , Sattler, Elisabeth Lilian Pia , Enama, Jean-Paul, Coulibaly, Bakary, Preux, Pierre‐Marie , Nsoesie, Elaine Okanyene , Tshilolo, Léon Muepu

Mayo Clinic

Journal of Global Health | October 18, 2024 | Volume: 14 | Issue: No issue available | Pages: No page available

10.7189/jogh.14.03042 | PMID 39421942 Get It

Abstract We044: MATURITY OF HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES PROMOTED BY BRACHYURY PRIMING
Kargaran, Parisa K, Garmany, Ramin , Stutzman, Marissa Joy, Sadeghian, Maryam, Ackerman, Michael J. , Behfar, Atta, Terzic, Andre, Garmany, Armin , Sadeghian, Maryam , Behfar, Atta , Terzic, André , Garmany, Ramin

Mayo Clinic

Circulation Research | October 9, 2024 | Volume: 135 | Issue: Suppl_1 | Pages: AWe044-AWe044

10.1161/res.135.suppl_1.we044 Get It

Introduction: Cardiac differentiation protocols enable derivation of cardiomyocytes (CM). from human induced pluripotent stem cell (iPS). However, limited tools are available to ensure enhanced iPS-CM maturation without the need for prolonged and complex culture. Research Question: This study assessed whether the mesodermal and cardiopoiesis inductor, Brachyury (T), complements standard cardiac differentiation and augments structural and functional maturation of iPS-CM. Aims: The impact of T mRNA introduction prior to initiation of cardiac differentiation was characterized on: i) cardiac transcription factor expression; ii) structural and functional hallmarks of maturity; and iii) cardiotoxicity. Methods: RT-qPCR was employed to monitor the expression of cardiac-specific transcription factors. Transmission electron microscopy enabled the assessment of cellular ultrastructure. Seahorse measurements were used to determine basal respiration. Fluo4 staining was used to measure calcium transients with external field stimulation. Cardiotoxicity was measured as the impact of doxorubicin on calcium handling and cell survival. Results: Transfection with T prompted early and sustained upregulation of the cardiac transcription factors Nkx2.5 (10-fold; FDR<0.001) and MEF2C (7.2-fold; FDR<0.001). Mitochondrial area was increased with T transfection (P<0.001) and T-transfected iPS-CM exhibited greater basal respiration (FDR<0.05), greater calcium handling resilience in response to field stimulation, and a more mature transient morphology. Following doxorubicin exposure T transfected iPS-CM exhibited a greater compromise in calcium handling (FDR<0.001), and exaggerated cell death. Conclusion: Induction of human iPS with T prior to initiation of cardiac differentiation enhanced signatures of structural and functional maturity, and provided more robust readouts of drug toxicity.
6931 Weight Trends and Predictors of Weight Gain in Breast Cancer Survivors
Tama, E , Hodge, David O. , Weston, Ainsley, Fahad, S, Ruddy, Kathryn J. , Olson, Joshua , Coach, F, Carter, R, D’Andre, Stacy D. , Hurtado, Maria D. , Tama, E, Weston, A, Acosta, Andrés , Shufelt, Chrisandra

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.054 Get It

Abstract Disclosure: M.D. Hurtado: None. E. Tama: None. D. Hodge: None. A. Weston: None. S. Fahad: None. K. Ruddy: None. J. Olson: None. F. Coach: None. R. Carter: None. S. D'Andre: None. A. Acosta: Consulting Fee; Self; Amgen Inc. Grant Recipient; Self; Vivus USA, Novo Nordisk. C. Shufelt: None. Background: Breast cancer (BC) is the most common cancer in women. Weight gain after treatment for early-stage BC is associated with a higher risk of recurrence. Excess adiposity is also a major risk factor for cardiovascular disease, the leading cause of non-BC related death in BC survivors. This study aimed to describe weight trends in a large cohort of BC survivors and to identify predictors of weight gain after BC diagnosis. Methods: This was a retrospective study of BC survivors from the prospectively consented Mayo Clinic Breast Cancer Registry, which has enrolled &gt;10,000 patients seen at least once at Mayo Clinic Rochester for a BC diagnosed within the prior year. We extracted data on weights at baseline, and years 1, 4, and 6 after BC diagnosis to generate longitudinal weight trajectory curves on the change from baseline. Weights were either reported by patients in the registry questionnaires or extracted from the electronic health records. We identified BC survivors with weight gain &gt;10% from baseline weight at years 1, 4, and 6. We then conducted univariable logistic regression analyses to identify predictors of &gt;10% weight gain. Variables considered included: demographics, anthropometrics, BC clinical and pathologic characteristics, BRCA 1 and 2 genetic mutation status, and treatment (surgery, neoadjuvant or adjuvant chemotherapy, and/or radiotherapy). Results: We included 4744 BC survivors, mostly white (95%) and non-Hispanic (91%), with a mean age and weight at BC diagnosis of 58 ± 13 years and 76 ± 18 kg. Most patients had clinical stage I (43%) and ER+ and PR+ BC (83% and 76%, respectively). Most patients underwent breast preserving surgery (62%), half received radiation (54%), one third (36%) received systemic chemotherapy, and two thirds (61%) received endocrine therapy. At one year after BC diagnosis the average weight change was negligible compared to baseline (mean difference -0.2 ± 8 kg), but there were small but significant average increases by years 4 and 6 (0.5 ± 9 kg, p=0.002; and 0.8 ± 10 kg, p&lt;0.001; respectively). At years 1, 4, and 6, the percentage of BC survivors gaining &gt;10% of their baseline weight was 10%, 15%, and 18%, respectively. Baseline characteristics associated with &gt;10% weight gain at 6 years included lower baseline weight (p&lt;0.001), younger age at BC diagnosis (p&lt;0.001), more advanced clinical and pathologic BC stage (p=0.008), ER+ and PR+ tumor biology (p=0.02 for both), BRCA2 mutation (p&lt;0.001), mastectomy (compared to breast preserving surgeries, p=0.008), the use of systemic chemotherapy treatment (p&lt;0.001), and the use of endocrine therapy (p=0.03). Conclusion: While most BC survivors do not experience weight gain after survivorship, 1 out 5 may experience excessive weight gain of more than 10%. Baseline anthropometric and BC-related variables are associated with excessive weight gain and could be used as predictors of weight gain in this population. Presentation: 6/3/2024
Decoded cardiopoietic cell secretome linkage to heart repair biosignature
Garmany, Armin , Arrell, D. Kent , Yamada, Satsuki , Jeon, Ryoung‐Hoon , Behfar, Atta , Park, Sungjo , Terzic, André , Jeon, Ryounghoon , Behfar, Atta , Terzic, Andre

Mayo Clinic

Stem Cells Translational Medicine | September 11, 2024 | Volume: 13 | Issue: 11 | Pages: 1144-1159

10.1093/stcltm/szae067 | PMID 39259666 Get It

Abstract Cardiopoiesis-primed human stem cells exert sustained benefit in treating heart failure despite limited retention following myocardial delivery. To assess potential paracrine contribution, the secretome of cardiopoiesis conditioned versus naïve human mesenchymal stromal cells was decoded by directed proteomics augmented with machine learning and systems interrogation. Cardiopoiesis doubled cellular protein output generating a distinct secretome that segregated the conditioned state. Altering the expression of 1035 secreted proteins, cardiopoiesis reshaped the secretome across functional classes. The resolved differential cardiopoietic secretome was enriched in mesoderm development and cardiac progenitor signaling processes, yielding a cardiovasculogenic profile bolstered by upregulated cardiogenic proteins. In tandem, cardiopoiesis enhanced the secretion of immunomodulatory proteins associated with cytokine signaling, leukocyte migration, and chemotaxis. Network analysis integrated the differential secretome within an interactome of 1745 molecules featuring prioritized regenerative processes. Secretome contribution to the repair signature of cardiopoietic cell-treated infarcted hearts was assessed in a murine coronary ligation model. Intramyocardial delivery of cardiopoietic cells improved the performance of failing hearts, with undirected proteomics revealing 50 myocardial proteins responsive to cell therapy. Pathway analysis linked the secretome to cardiac proteome remodeling, pinpointing 17 cardiopoiesis-upregulated secretome proteins directly upstream of 44% of the cell therapy-responsive cardiac proteome. Knockout, in silico, of this 22-protein secretome-dependent myocardial ensemble eliminated indices of the repair signature. Accordingly, in vivo, cell therapy rendered the secretome-dependent myocardial proteome of an infarcted heart indiscernible from healthy counterparts. Thus, the secretagogue effect of cardiopoiesis transforms the human stem cell secretome, endows regenerative competency, and upregulates candidate paracrine effectors of cell therapy-mediated molecular restitution.
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
Chibaudel, Benoist , Raeisi, Morteza , Cohen, Romain , Yothers, Greg , Goldberg, Richard M. , Wolmark, Norman , Yoshino, Takayuki , Schmoll, Hans‐Joachim , George, Thomas J. , Shacham‐Shmueli, Einat , Gramont, Aimery de , Wolmark, Norman , Yoshino, Takayuki , Schmoll, Hans-Joachim , George, Thomas J , Shi, Qian , André, Thierry , De Gramont, Aimery , Yothers, Greg , Chibaudel, Benoist , Cohen, Romain , Bachet, Jean‐Baptiste , Kerr, Rachel , Lonardi, Sara , Shi, Qian , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | September 4, 2024 | Volume: 42 | Issue: 35 | Pages: 4187-4195

10.1200/jco.24.00394 | PMID 39231393 Get It

PURPOSE The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit in high-risk stage II CC. We performed a pooled analysis of pivotal MOSAIC and C-07 studies evaluating FPOX for the treatment of high-risk stage II CC according to prognostic factors, number of high-risk factors, and current clinicopathologic risk classification on the basis of T stage, tumor perforation, and number of lymph nodes examined. PATIENTS AND METHODS One thousand five hundred and ninety-five patients with stage II CC receiving FP or FPOX were pooled. The overall survival (OS) benefit of OX was analyzed using Kaplan-Meier curves and unadjusted Cox models stratified by study. Three thousand and fifty-nine patients with stage III CC were used only for interaction tests between the allocated chemotherapy and stage. RESULTS In the pooled analysis of stage II patients, independent prognostic factors in multivariable analysis were sex, age, perforation/obstruction, and tumor sidedness. There was a significant interaction in OS between stage and allocated chemotherapy with hazard ratios (HRs) of 1.03 for stage II (95% CI, 0.82 to 1.29; P = .813) and 0.82 for stage III (95% CI, 0.73 to 0.92; P = .001; P int = .073). There was no benefit from the addition of OX to FP for any of the prognostic factors. The number of high-risk factors tested was not predictive of OX benefit. According to the currently agreed clinicopathologic risk classification, no OS benefit of OX was observed, as HR was 0.86 (95% CI, 0.63 to 1.18; P = .349). CONCLUSION No OS benefit of adjuvant OX was found in high-risk stage II CC, regardless of the definition used to characterize tumors as having a high risk for recurrence. Hence, our analysis suggests that OX should not be the standard of care for adjuvant chemotherapy for stage II CC, even in high-risk patients.
Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials
Campbell, Nancy , Hillman, Shauna L., Harlos, Elizabeth S., Stein, David , Chan, Miranda Y., Chow, Selina , Elrahi, Cassandra , Quina, Andre , Kokolus, Maeve C., Casagni, Michelle , Weiss, Matthias , Anderson, Daniel M. , Hoff, Olivia C., Rivera, Donna R. , Mandrekar, Sumithra J. , Piantadosi, Steven , Stadler, Walter M , Piantadosi, Steven , George, Suzanne , Campbell, Nancy, Stadler, Walter M. , Kluetz, Paul Gustav

Mayo Clinic

Cancer | August 28, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35528 | PMID 39192753 Get It

AbstractBackgroundThe use of electronic health record (EHR) data for research is limited by a lack of structure and a standard data model. The objective of the ICAREdata (Integrating Clinical Trials and Real‐World Endpoints Data) project was to structure key research data elements in EHRs using a minimal Common Oncology Data Elements (mCODE) data model to extract and transmit data.MethodsThe ICAREdata project captured two EHR data elements essential to clinical trials: cancer disease status and treatment plan change. The project was implemented in clinical sites participating in Alliance for Clinical Trials in Oncology trials. Data were extracted from EHRs and sent by secure Fast Healthcare Interoperability Resource messaging (a standard for exchanging EHRs) to a database. Selected elements were compared with corresponding data from the trial's electronic data capture (EDC) system, Medidata Rave.ResultsBy December 2023, data were extracted and transmitted from 10 sites for 35 patients, involving 367 clinical encounters across 15 clinical trials. Data through March 2023 demonstrated that concordance for the elements treatment plan change and cancer disease status was 79% and 34%, respectively. When disease evaluation was reported by both EHR and EDC (n = 15), there was 87% agreement on cancer disease status.ConclusionsDocumentation, extraction, and aggregation of structured data elements in EHRs using mCODE and ICAREdata methods is feasible in multi‐institutional cancer clinical trials. EDC as a reference data set allowed assessment of the completeness of EHR data capture. Future initiatives will focus on elements with shared definitions in clinical and research environments and efficient workflows.Plain Language Summary Clinical trials use electronic case report forms to report data, and data must be manually entered on these forms, which is costly and time consuming. ICAREdata methods use structured, organized data from clinical trials that can be more easily shared instead having to enter free text into electronic health records.
Immune Effector Cell-Associated Enterocolitis following Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma
Song, Jinming , Lekakis, Lazaros J. , Samraj, Annie N. , Naresh, Kikkeri N. , Vazquez‐Martinez, Mariola , Mikkilineni, Lekha , Corraes, Andre De Menezes Silva , Kalariya, Nilesh, Patel, Krina K. , Ferreri, Christopher J. , Voorhees, Peter M. , Valdes, Cesar Rodriguez , Cowan, Andrew J., Sborov, Douglas W. , Lin, Yi, Naresh, Kikkeri N , Fortuna, Gliceida Galarza , Banerjee, Rahul , Fernandez‐Pol, Sebastian , Baz, Rachid , Spiegel, Jay Y. , Gubatan, John , Sidana, Surbhi , Shim, Kevin G. , Fonseca, Rafaël , Richard, Shambavi , Hansen, Doris K. , Wang, Yinghong

Mayo Clinic

No container title available | August 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4727434/v1 Get It

Abstract Background: Several immune effector cell (IEC) therapies have been approved for multiple myeloma (MM), including chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We report 14 cases of IEC-associated enterocolitis, in five cases fatal, following CAR-T therapy in MM. Methods: We performed a retrospective analysis of cases of diarrhea, enterocolitis, or colitis following commercial ide-cel or cilta-cel (including out-of-specification products) at 10 centers within the United States Myeloma Immunotherapy Consortium. Patients were treated according to the local standard of care at each participating center. Results: We identified 14 cases of IEC-associated enterocolitis out of 1159 CAR-T infusions, corresponding to a 1.2% incidence (0.2% for ide-cel and 2.3% for cilta-cel). This proportion excludes 3 cases of potential or confirmed T-cell lymphoproliferative disorders of the bowel. Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 79 days (range: 22-210 days) after CAR-T therapy and a median of 74 days after cytokine release syndrome resolution (range: 2-202 days). Biopsies uniformly demonstrated inflammation, with specific findings including intra-epithelial lymphocytosis, crypt dropout on colon biopsies, and villous blunting on duodenal biopsies. Systemic corticosteroids were initiated in 10 patients (71%) a median of 26 days (range: 1-80 days) following symptom onset. Only 40% of steroid-treated patients had symptomatic improvement; subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. With a median follow-up of 224 days, n = 4 have had diarrhea resolution, n = 5 have had improved or stable symptoms, and n = 5 (36%) have died from IEC-associated enterocolitis or treatment-emergent infections. Conclusions: IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy characterized by non-bloody diarrhea typically beginning 1-3 months after infusion. Thorough diagnostic workup (including evaluation for potential T-cell malignancies) and appropriate management with an expert gastroenterologist are essential. Further research is critical to understand the pathogenesis of this novel toxicity. In the interim, the early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.